Vermillion's Shares Spike to Lead Nasdaq | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of molecular diagnostics firm Vermillion rose 23 percent on Monday to close at $8.95, leading all gainers on the Nasdaq for the day.

The reason for the spike is unclear, as the firm didn't disclose any news or file any documents with the US Securities and Exchange Commission. Trading in the firm's shares also was heavy, with 603,100 shares trading hands, compared to its average daily volume of around 128,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.